1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 09, 2025 06:03 ET (10:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.